➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Baxter
Moodys
Colorcon
Mallinckrodt

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,463,193

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,463,193
Title:Individual 5-fluorouracile dose optimization in folfiri treatment
Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.
Inventor(s): Gamelin; Erick (Bouchemaine, FR), Boisdron-Celle; Michele (Saint Leger Des Bois, FR), Morel; Alain (Juigne Sur Loire, FR)
Assignee: INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR)
Application Number:13/121,103
Patent Claims:see list of patent claims

Details for Patent 9,463,193

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR) UNIVERSITE D\'ANGERS (Angers, FR) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.